Fig. 1
Inhibition effects of PVE30 at different stages of HSV infection in vitro. Vero cells infected with 100 PFU/well HSV-1/KOS or HSV-2/G were treated with PVE30 at various stages of HSV infection, and the EC50 values were determined by a plaque reduction assay. (A) Simple diagram of PVE30 treatment at different stages of HSV infection. (B) Representative images of the plaque reduction assay with PVE30 (25 μg/mL) added at different stages of HSV infection. (C) Anti-HSV effects of PVE30 on pre-infection, attachment, penetration and post-infection stage. Values represent the mean ± S.D. from three independent experiments with each treatment performed in duplicate. *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, vs. virus control group